---
canonical_name: Oxandrolone
alternate_names: Oxandrin, Anavar, Lonavar, Protivar, Vasorome, Oxandrolonum
canonical_topic: Oxandrolone for Muscle Preservation
short_topic_lc: oxandrolone_muscle
creation_date: 2026-0917-2339
creator_ai_fullname: Opus 5
ep_keywords: AAS, Anabolic-Androgenic Steroids, Anabolic Steroids
---

# Oxandrolone for Muscle Preservation
<section id="top" markdown="1"></section>

Evidence Review created on 09/17/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5

**Also known as:** Oxandrin, Anavar, Lonavar, Protivar, Vasorome, Oxandrolonum

  
## Motivation

<!-- Author's note: this Motivation section was written last, after every other section of this review was complete, so that it reflects the full scope of the evidence surveyed rather than a preliminary impression of the topic. -->

Oxandrolone is a synthetic relative of testosterone, given as an oral medication, designed to build and hold muscle tissue while producing less of the masculinising effect of the hormone it was modelled on. Its interest is straightforward: skeletal muscle is the body's largest store of protein, and losing it — through illness, injury, enforced stillness, or the slow attrition of ageing — tracks closely with frailty, disability, and a shortened span of healthy life.

For decades it was used in hospitals to help people regain weight and muscle after severe burns, major surgery, or long infection, and it remains one of the very few compounds ever licensed specifically to reverse tissue loss. Manufacture in the United States has since ceased, yet interest in it persists among people who want to protect muscle during weight loss, injury recovery, or later life.

This review examines what controlled human research shows about oxandrolone's effect on muscle mass, strength, and recovery; what it costs in liver strain, blood fat changes, and hormonal shutdown; and how firm the evidence is on each side of that exchange.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

High-level overviews of oxandrolone and of androgen therapy for muscle preservation, drawn from expert platforms and from narrative clinical literature.

<!-- Author's search statement: a real-time search was run for high-level, topic-relevant content. Web searches were run for each priority platform paired with the intervention ("Peter Attia oxandrolone", "hubermanlab.com anabolic steroids oxandrolone", "Rhonda Patrick oxandrolone", "Chris Kresser oxandrolone", "lifeextension.com oxandrolone", "lifespan.io oxandrolone"). PubMed was searched for narrative reviews and editorials (oxandrolone[tiab] AND safety/adverse/hepatic/liver; oxandrolone[tiab] AND elderly/older/aging/sarcopenia). Priority-platform pages were retrieved with d-browser, falling back to d-proxy-2 where d-browser returned an access-denied page. Systematic reviews and meta-analyses were deliberately excluded here and routed to the Systematic Reviews section. -->

- [#274 – Performance-enhancing drugs and hormones: risks, rewards, and broader implications for the public](https://peterattiamd.com/derekmpmd/) - Peter Attia

  A long-form conversation on anabolic-androgenic steroids (synthetic testosterone relatives that build tissue), the class oxandrolone belongs to, covering dosing logic, lipid and liver costs, and how clinical use diverges from performance use.

- [The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety](https://pubmed.ncbi.nlm.nih.gov/15025546/) - Orr & Fiatarone Singh, 2004

  The deepest single narrative appraisal of oxandrolone across anabolic (tissue-building) and catabolic (tissue-breakdown) settings, spanning burns, HIV (human immunodeficiency virus) wasting, and neuromuscular disease, with an explicit efficacy-versus-harm accounting.

- [A Reappraisal of Oxandrolone in Burn Management](https://pubmed.ncbi.nlm.nih.gov/35832568/) - Kopel et al., 2022

  A narrative re-examination of eighteen studies of oxandrolone in hypermetabolism (the sustained surge in energy and protein burn that follows major injury), summarising where the benefit is real and where it is absent.

- [Testosterone and anabolic therapy to recover strength, function, and quality of life after critical illness](https://pubmed.ncbi.nlm.nih.gov/41954304/) - Wischmeyer, 2026

  Places oxandrolone alongside testosterone, creatine, and beta-hydroxy-beta-methylbutyrate as muscle-sparing options after critical illness, and states plainly which of them carries the strongest clinical evidence.

- [Catabolic Wasting - Cachexia and Sarcopenia](https://www.lifeextension.com/protocols/health-concerns/catabolic-wasting) - Maureen Williams & Shayna Sandhaus

  A practitioner-facing protocol that situates oxandrolone within the broader management of cachexia (disease-driven wasting) and sarcopenia (age-related muscle loss), including its comparative tolerability in women.

Note on priority experts: relevant, substantive content was found for Peter Attia and Life Extension only. Searches of Rhonda Patrick's foundmyfitness.com, hubermanlab.com, chriskresser.com, and lifespan.io returned no item that discusses oxandrolone or androgen therapy for muscle preservation in substantial depth — the closest matches are general testosterone-optimisation episodes in which oxandrolone appears only as a passing mention, which does not meet the high-level-overview bar used here. Five qualifying sources were found, so the list is not padded.

  
## Grokipedia

<!-- Author's search statement: grokipedia.com was searched directly for the intervention using the Section 5 retrieval tiers in order. Tier 1, d-browser: browser_navigate to https://grokipedia.com/search?q=Oxandrolone returned the site's own search results page reporting 75 hits, with a dedicated primary article "Oxandrolone" at /page/Oxandrolone; browser_navigate to that page returned the genuine article. No further tier was required. -->

- [Oxandrolone](https://grokipedia.com/page/Oxandrolone)

  The site's primary page for the compound, covering its dihydrotestosterone-derived chemistry, licensed indications, and the burn and wasting literature in a single continuous reference article.

  
## Examine

<!-- Author's search statement: examine.com was searched directly for the intervention using the Section 5 retrieval tiers in order. Tier 1, d-browser: browser_navigate to https://examine.com/search/?q=oxandrolone returned a "Vercel Security Checkpoint" bot-detection interstitial, not the site. Tier 2, d-fetch: returned HTTP 429 (rate limited). Tier 3, d-proxy-1: unavailable for this retrieval. Tier 4, d-proxy-2 scrape_as_markdown: returned the genuine Examine search results page, which states "Sorry, there are no search results for oxandrolone." -->

No Examine article exists for oxandrolone. Examine.com covers dietary supplements and does not typically cover prescription medications; oxandrolone is a prescription-only, Schedule III controlled anabolic steroid, so its absence is expected.

  
## ConsumerLab

<!-- Author's search statement: consumerlab.com was searched directly for the intervention using the Section 5 retrieval tiers in order. Tier 1, d-browser: browser_navigate to https://www.consumerlab.com/search/?q=oxandrolone returned the genuine ConsumerLab search results page, whose heading reads "Sorry, we didn't find any results for oxandrolone". No further tier was required. -->

No ConsumerLab article exists for oxandrolone. ConsumerLab independently tests dietary supplements and does not typically cover prescription medications; as a prescription-only controlled substance with no over-the-counter form, oxandrolone falls outside its testing remit.

  
## Systematic Reviews

This section lists the systematic reviews and meta-analyses (statistical poolings of results across multiple studies) bearing on oxandrolone's effect on lean body mass (the non-fat tissue that includes muscle) and on its safety, noting that the underlying trials come largely from a small circle of burn and academic centres, some of them supported by the drug's former manufacturer, Bio-Technology General (later Savient), a financial interest that bears on how uniformly favourable the efficacy findings read.

<!-- Author's search statement: a real-time PubMed search was performed for the intervention combined with the systematic review and meta-analysis publication types (query: oxandrolone AND (systematic review[pt] OR meta-analysis[pt]), 19 records returned), supplemented by oxandrolone[tiab] AND (safety OR adverse OR hepatic OR liver). Selection was prioritised by direct relevance to the intervention, study size, recency, and coverage of both the claimed effect and the principal risk. -->

- [Oxandrolone for burn patients: a systematic review and updated meta-analysis of randomized controlled trials from 2005 to 2025](https://pubmed.ncbi.nlm.nih.gov/41023744/) - Lou et al., 2025

  The largest and most recent pooling: 14 randomised controlled trials (RCTs — studies allocating treatment by chance), 2,822 patients, reporting both lean-mass gain and hepatotoxicity.

- [Oxandrolone in the Treatment of Burn Injuries: A Systematic Review and Meta-analysis](https://pubmed.ncbi.nlm.nih.gov/31504621/) - Ring et al., 2020

  Pools 31 trials and observational studies; finds gains in lean mass, bone density, and wound healing without an increase in progressive liver dysfunction.

- [The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/26454425/) - Li et al., 2016

  Fifteen trials, 806 participants; the most granular figures available for lean-mass preservation, nitrogen retention, and length of stay, with paired safety outcomes.

- [Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome](https://pubmed.ncbi.nlm.nih.gov/31684688/) - Mohamed et al., 2019

  A Cochrane review in Turner syndrome (a chromosomal condition causing short stature in girls); the cleanest pooled evidence on the principal masculinising harm, voice deepening.

- [Anabolic steroids for treating pressure ulcers](https://pubmed.ncbi.nlm.nih.gov/28631809/) - Naing & Whittaker, 2017

  A Cochrane review of a stopped-for-futility oxandrolone trial; important negative evidence and the source of a non-serious adverse-event estimate.

  
## Mechanism of Action

Oxandrolone is a synthetic derivative of dihydrotestosterone (the body's most potent natural androgen), altered in two places: the second carbon of the steroid A-ring is replaced by an oxygen atom, and a methyl group is attached at the 17α position. Both changes let the molecule survive first passage through the liver, giving oral bioavailability near 97%.

Its primary action is binding the androgen receptor (the protein inside muscle cells that reads testosterone signals). Receptor activation raises the rate at which muscle assembles new contractile protein, recruits satellite cells (muscle stem cells that donate nuclei to existing fibres), and raises circulating insulin-like growth factor 1 (a systemic growth signal). A second, anti-catabolic arm is competition at the glucocorticoid receptor, blunting the cortisol-driven protein breakdown that dominates burns, sepsis, and immobilisation.

Key pharmacological properties: elimination half-life roughly 9.4 hours in adults and about 13.3 hours past age 65; highest affinity in skeletal muscle, with secondary distribution to bone, liver, and skin; about 28% excreted unchanged in urine, with only limited hepatic metabolism because the 2-oxa substitution resists the usual cytochrome P450 enzymes (CYP, the liver's main drug-processing family) including CYP3A4; no conversion to oestrogen, since it is not an aromatase substrate, and no further 5α-reduction, since it is already 5α-reduced.

A competing mechanistic reading holds that part of the measured lean-mass gain is intracellular water rather than contractile protein: in the best-instrumented older-adult trial, total body water rose by almost the same amount as lean mass ([Schroeder et al., 2004](https://pubmed.ncbi.nlm.nih.gov/14578370/)).

  
## Historical Context & Evolution

Oxandrolone was synthesised at Searle Laboratories in 1962 and marketed as Anavar from 1964. Its intended use was never athletic: it was licensed to restore weight lost to major surgery, chronic infection, or trauma, to offset corticosteroid-driven protein loss, and to relieve osteoporotic bone pain. Paediatric endocrinologists used it to advance growth in delayed puberty and Turner syndrome.

Searle withdrew it in 1989, amid scrutiny that made anabolic steroids controlled substances. It returned in 1995 under Bio-Technology General as Oxandrin, for advanced human immunodeficiency virus wasting. Those trials reported dose-dependent gains in body cell mass and strength alongside falling protective cholesterol and rising liver enzymes ([Grunfeld et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16540931/)) — the two-sided result that has followed it ever since.

Through the 2000s attention moved to burn units, where Galveston and multicentre American investigators reported shorter stays and preserved lean mass ([Wolf et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16566555/), [Porro et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22463890/)), while a parallel trial in ventilated surgical patients found longer ventilation ([Bulger et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15319718/)). That discordance stands unresolved. Interest beyond the hospital came from placebo-controlled trials in healthy men aged 60 to 87, where a drug built for catabolic illness also added lean mass and lifting strength in ordinary ageing ([Schroeder et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16424293/)) — the finding that carried it into the muscle-preservation conversation, though reviewers noted it was still untested against sarcopenia. Rather than being overturned, the findings have narrowed: firm in severe burns, less clear outside. United States manufacture ceased in the 2020s and comparison shifted to injectable testosterone.

  
## Expected Benefits

<!-- Author's search statement: before writing this section a dedicated search for the complete benefit profile was run across clinical and expert sources: PubMed (oxandrolone muscle mass lean body mass randomized; oxandrolone[tiab] AND elderly/older/aging/sarcopenia; oxandrolone[tiab] AND burn AND multicenter; oxandrolone HIV wasting; oxandrolone[tiab] AND lipoprotein; oxandrolone AND muscular dystrophy/neuromuscular), ClinicalTrials.gov (interventionQuery oxandrolone, 20 registered studies), and web searches of the priority expert platforms. Every benefit domain surfaced by those searches — lean mass, strength, recovery from catabolic injury, fat and visceral fat, bone, protein kinetics, respiratory function, insulin sensitivity — is represented below. -->

Benefits are framed for a risk-aware adult who is already training and eating to support muscle and is weighing a pharmacological addition, not for an average patient receiving it in hospital.

### High 🟩 🟩 🟩

#### Lean Body Mass Preservation and Accrual

Oxandrolone raises whole-body lean tissue and blunts its loss under catabolic stress, acting through androgen receptors in skeletal muscle. In healthy men aged 60 to 87, 20 mg daily added about 3.0 kg of lean mass over 12 weeks against placebo ([Schroeder et al., 2004](https://pubmed.ncbi.nlm.nih.gov/14578370/)); in sedentary older women 10 mg daily added 2.6 kg on top of supervised resistance training ([Mavros et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25899102/)). Pooled burn trials show the same preservation during severe catabolism ([Li et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26454425/)). Gains reverse after withdrawal.

**Magnitude:** +3.0 kg whole-body lean mass over 12 weeks at 20 mg daily in men aged 60 to 87, and +2.6 kg at 10 mg daily in older women already resistance training; in severe burns, roughly 5 percentage points less lean-mass loss during the rehabilitative phase and about 10.8% more lean mass at 12 months.

#### Maximal Muscle Strength ⚠️ Conflicted

Strength rises with lean mass in untrained older men, 74% to 96% of the twelve-week gain arriving by six weeks ([Schroeder et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16424293/)). It also raised strength gains from resistance training in men with wasting ([Strawford et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10208143/)), and slowed strength loss on quantitative testing in Duchenne muscular dystrophy (an inherited muscle-wasting disease), a labelled indication ([Fenichel et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11320181/)). Against this, resistance-trained older women gained none ([Mavros et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25899102/)). The net reading: it adds strength where training is minimal, little where a real stimulus exists.

**Magnitude:** +4.8% to +9.3% one-repetition maximum (the heaviest single lift achievable) across four exercises after 6 to 12 weeks in untrained older men; a manual muscle score of +0.035 versus −0.140 on placebo over six months in Duchenne dystrophy, with the average of four quantitative muscle tests significantly improved; no measurable added strength over resistance training alone in trained older women.

#### Faster Recovery from Severe Catabolic Injury

The clinical expression of preserved muscle protein is a shorter recovery. A multicentre randomised trial in adults with 20–60% body-surface burns was stopped early at interim analysis because hospital stay was markedly shorter on oxandrolone ([Wolf et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16566555/)); poolings reproduce shorter stay and reduced weight and nitrogen loss ([Li et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26454425/), [Ring et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31504621/)). Donor-site healing is contested — faster in those two, unchanged in a pooling restricted to trials from 2005 onward ([Lou et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41023744/)), a narrower set. No mortality benefit has ever been shown.

**Magnitude:** hospital stay 31.6 versus 43.3 days in the multicentre adult burn trial; pooled estimates give 3.0 fewer days in the catabolic phase, and donor-site healing 4.4 days faster in the two poolings that report a gain against no change in the 2005-onward pooling.

#### Reduction in Fat Mass and Visceral Fat ⭕️ Not Central to Muscle Preservation

This bears on body composition and cardiometabolic risk rather than on muscle preservation itself. In older men, 20 mg daily cut total and trunk fat and reduced visceral adipose tissue, with a parallel improvement in an insulin-sensitivity index; unusually, most of the fat loss persisted three months after the drug was stopped, while the lean-mass gain did not ([Schroeder et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15472177/)). A randomised trial in older women reproduced the whole-body fat loss ([Mavros et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25899102/)).

**Magnitude:** −1.8 kg total fat and −20.9 cm² visceral adipose tissue over 12 weeks at 20 mg daily in older men; about 83% of the fat reduction still present 12 weeks after stopping.

#### Growth Promotion and Final Adult Height ⭕️ Not Central to Muscle Preservation

This bears on skeletal growth in children, not on muscle preservation in adults. Pooled randomised trials in girls with Turner syndrome already receiving growth hormone found that adding oxandrolone raised final adult height, an effect the review graded moderate certainty ([Mohamed et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31684688/)). Paediatric endocrinologists adopted the drug on the same basis in constitutionally delayed puberty. The effect depends on open growth plates and is therefore unavailable to adults.

**Magnitude:** +2.7 cm in final adult height (95% confidence interval 1.3 to 4.1 cm — the range within which the true value plausibly lies) pooled across five randomised trials in 270 girls given growth hormone with or without oxandrolone.

### Medium 🟩 🟩

#### Bone Mineral Content Accrual ⭕️ Not Central to Muscle Preservation

This bears on skeletal integrity, not on muscle. A single long-term randomised trial gave oxandrolone for twelve months after severe paediatric burns and found higher bone mineral content and height percentile persisting for up to five years, apparently mediated by insulin-like growth factor 1 ([Porro et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22463890/)). A later pooling reports the same direction but is dominated by that trial ([Ring et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31504621/)), and no equivalent trial exists in ageing adults.

**Magnitude:** the direction is a consistent increase in bone mineral content that persists up to five years and is largest in those treated between ages 7 and 18; the source trial reports percentile and content improvements without publishing an absolute effect figure, and the literature gives no pooled outcome number.

#### Improved Physical Function and Scar Quality After Massive Burns

A single large randomised trial gave oxandrolone together with propranolol for a year after massive paediatric burns and found reduced scar severity, greater scar pliability, and improved patient-reported general and emotional health ([Herndon et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30048322/)). The cited evidence tested oxandrolone in combination with propranolol, not alone, so the contribution of each agent cannot be separated. Function, rather than mass, is the endpoint that matters most for the goal, and this is the only trial to report it favourably.

**Magnitude:** the direction is a reduction in scar severity and an increase in pliability with improved patient-reported physical and emotional function over 24 months; the trial reports statistical significance on ordinal scar scales and patient-reported measures without a single summary effect figure, and no outcome number is available for oxandrolone alone.

### Low 🟩

#### Increased Muscle Protein Synthesis and Nitrogen Retention

Oxandrolone raises the fractional synthetic rate of muscle protein (the share rebuilt per hour) by roughly half within two weeks in older women and five days in older men, in an uncontrolled design ([Sheffield-Moore et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16895962/)). Controlled work shows parallel nitrogen retention ([Strawford et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10208143/)).

**Magnitude:** fractional synthetic rate 0.073 to 0.115 %/hour over 14 days in older women; nitrogen retention 5.6 versus 3.8 g/day against placebo in men on resistance training.

#### Respiratory Muscle Function After Spinal Cord Injury

An eight-week uncontrolled pilot in ten men with motor-complete tetraplegia (paralysis of all four limbs) found modest lean-mass gains, concentrated in the arms, with small average improvement in lung-function tests ([Halstead et al., 2010](https://pubmed.ncbi.nlm.nih.gov/19581914/)). There was no control group, and lipids and liver enzymes worsened.

**Magnitude:** total lean mass +1.9%, arm lean mass +5.4%, pooled pulmonary function tests +2.2% over eight weeks at 20 mg daily.

#### Improved Insulin Sensitivity Markers ⭕️ Not Central to Muscle Preservation ⚠️ Conflicted

This bears on metabolic health, not muscle. A calculated insulin-sensitivity index improved over twelve weeks in older men, though the marker is derived rather than a clamp measurement ([Schroeder et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15472177/)); prescribing information instead lists decreased glucose tolerance for the class. The net reading favours the controlled measurement.

**Magnitude:** quantitative insulin sensitivity check index +0.0041 over 12 weeks at 20 mg daily in overweight men aged 60 to 87.

### Speculative 🟨

#### Mitigation of Age-Related Sarcopenia

No trial takes clinical sarcopenia outcomes — disability, falls, independence — as an endpoint. Randomised work in older adults added lean tissue without added strength or physical performance beyond resistance training, so the basis remains extrapolation.

#### Preservation of Muscle During Pharmacological Weight Loss

No human study has given oxandrolone alongside a weight-loss medication. The basis is mechanistic only: the drug adds lean mass while lowering fat, the pattern such regimens would require.

  
## Benefit-Modifying Factors

- **Androgen receptor CAG repeat length:** the receptor gene carries a variable glutamine-coding repeat; shorter repeats give a more transcriptionally active receptor and, in androgen-therapy studies generally, a larger body-composition response at the same dose. Not yet tested specifically with oxandrolone.

- **Baseline testosterone:** response is largest where endogenous androgen is low. Men starting below 10.4 nmol/L (300 ng/dL) lost significantly more total fat and abdominal subcutaneous fat than men starting higher, suggesting the anabolic margin is widest in androgen-deficient states.

- **Baseline lean mass and protein intake:** the drug supplies signal, not substrate. Gains reported in trials came with hospital-grade or supervised protein and energy provision; under-eating protein caps the response regardless of dose.

- **Sex-based differences:** muscle protein synthesis rises in both sexes on different timelines — by day five in older men, by day fourteen in older women at 15 mg daily versus 20 mg. Women respond more slowly, at lower exposure.

- **Age-related considerations:** the mass and strength response is preserved into the eighties, but leg power and walking speed did not improve in men aged 60 to 87. Those at the upper end gain tissue without a demonstrated gain in function.

- **Pre-existing health conditions:** the effect scales with catabolic drive — largest in severe burns and wasting, absent in ventilated surgical and trauma patients, and absent for pressure-ulcer healing in a trial stopped for futility.

  
## Potential Risks & Side Effects

<!-- Author's search statement: before writing this section a dedicated search of the complete side effect profile was performed against drug reference sources and the primary literature: the drugs.com oxandrolone monograph (retrieved via d-proxy-2 scrape_as_markdown; confirms United States discontinuation, Schedule III status, the anabolic-steroid class warning on hepatic, splenic and vascular events, virilisation, and contraindications), plus PubMed searches (oxandrolone[tiab] AND safety/adverse/hepatic/liver; oxandrolone[tiab] AND lipoprotein HDL cholesterol; oxandrolone[tiab] AND testosterone suppression/gonadotropin/virilization) and the pooled safety data in the burn meta-analyses. -->

Risks are framed for a healthy, risk-aware adult using oxandrolone electively, for whom the lipid and endocrine costs matter more than they would for a hospitalised patient with weeks to live.

### High 🟥 🟥 🟥

#### Hepatic Transaminase Elevation

The most frequent adverse effect. The 17α-methyl group that protects the molecule from hepatic breakdown also stresses liver cells, producing transaminitis (a rise in liver enzymes signalling cell injury). In pooled randomised burn trials the adult rate was roughly four times placebo ([Lou et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41023744/)); a multicentre series found it in four of every ten treated adults ([Kiracofe et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31220261/)). It is typically reversible on withdrawal and did not become progressive liver dysfunction in pooled analysis ([Ring et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31504621/)).

**Magnitude:** 19% versus 5% on placebo in pooled adult burn trials; 41.4% of 309 adults exceeded 100 units/L after a median 13 days of treatment in a multicentre series.

#### Adverse Shift in Blood Lipids

Oxandrolone markedly raises hepatic lipase activity (the liver enzyme that strips fat and cholesterol out of circulating lipoprotein particles), stripping protective high-density lipoprotein cholesterol (HDL-C, the particle that returns cholesterol to the liver) while raising low-density lipoprotein cholesterol (LDL-C, the atherogenic particle). The shift was significant in a randomised trial in older men ([Schroeder et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15472177/)), reproduced across oxandrolone doses in a 262-man randomised trial ([Grunfeld et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16540931/)), and reproduced again in tetraplegia ([Halstead et al., 2010](https://pubmed.ncbi.nlm.nih.gov/19581914/)). It is largely reversible within weeks of stopping.

**Magnitude:** HDL-C fell 0.49 mmol/L (about 19 mg/dL) and directly measured LDL-C rose 0.57 mmol/L over 12 weeks in older men; an uncontrolled tetraplegia series recorded HDL-C −31.8% and LDL-C +41.2%.

#### Virilisation in Women

Androgenic signalling produces virilisation (the development of male traits): voice deepening, facial and body hair, acne, menstrual disruption, and clitoral enlargement. Voice change is the effect most consistently reported and is the one least likely to reverse. Pooled randomised trials in girls receiving oxandrolone with growth hormone reported adverse events, predominantly virilising, more often on oxandrolone, though the pooled estimate was imprecise and the evidence rated low certainty ([Mohamed et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31684688/)). Oxandrolone is nonetheless the least virilising of the orally active anabolic steroids ([Orr & Fiatarone Singh, 2004](https://pubmed.ncbi.nlm.nih.gov/15025546/)).

**Magnitude:** risk ratio 1.81 (an 81% higher rate; 95% confidence interval 0.83 to 3.96) for adverse events, mainly virilising effects such as voice deepening, across two pooled trials with 170 participants.

### Medium 🟥 🟥

#### Suppression of Endogenous Testosterone and Gonadotropins

Exogenous androgen signals the hypothalamic-pituitary-gonadal axis (the brain-to-gonad loop that sets testosterone output) to shut down. In a 262-man randomised trial, oxandrolone significantly suppressed luteinising hormone and follicle-stimulating hormone (the two pituitary signals driving the testes), sex hormone-binding globulin, and both total and free testosterone across every dose tested ([Grunfeld et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16540931/)). The same shutdown suppresses sperm production and can shrink the testes, the class effects behind reduced male fertility on treatment. Recovery time after withdrawal has not been formally characterised.

**Magnitude:** the direction is a dose-related fall in luteinising hormone, follicle-stimulating hormone, sex hormone-binding globulin, and total and free testosterone, holding across 20, 40, and 80 mg daily over 12 weeks; the trial reports the suppression as statistically significant without publishing percentage changes, and no other trial quantifies it.

#### Prolonged Mechanical Ventilation in Critical Illness ⚠️ Conflicted

A randomised, placebo-controlled trial in surgical and trauma patients needing more than seven days of ventilation found the oxandrolone arm spent significantly longer on the ventilator and longer in intensive care, with the authors proposing enhanced collagen deposition and fibrosis in late lung injury ([Bulger et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15319718/)). Pooled burn analyses found no change in ventilation requirement ([Ring et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31504621/)). The net reading is that the harm signal is real but confined to patients with established acute lung injury, a state that does not describe elective users.

**Magnitude:** 21.7 versus 16.4 days of mechanical ventilation (p = 0.03, the p-value being the probability that a difference this large would arise by chance alone) in 41 ventilator-dependent surgical and trauma patients; pooled burn data show no difference in ventilation requirement.

### Low 🟥

#### Venous Thromboembolic Events

A severity-matched analysis of 813 adults with major burns across twelve centres found significantly more venous thromboembolism (clots in veins, which can travel to the lungs) with anabolic therapy, and higher mortality on oxandrolone than testosterone ([Hong et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42518198/)). It is observational and pools anabolic agents.

**Magnitude:** the direction is an increased rate of venous thromboembolic events with anabolic therapy versus none (p = 0.019) in a 813-patient cohort matched for injury severity and patient characteristics; the report gives significance without publishing the event rates for each arm.

#### Fluid Retention and Peripheral Oedema

Androgens promote sodium and water retention, producing ankle swelling and rapid weight gain that can be mistaken for lean-tissue accrual. The pooled burn trials record it only within a combined mild-side-effect category ([Lou et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41023744/)). Concurrent corticosteroids amplify it, and it matters most with heart or kidney impairment.

**Magnitude:** Not quantified in available studies. The randomised trials pool oedema with liver-enzyme elevation into a single mild-side-effect category, so no isolated oedema rate has ever been published.

#### Mood Disturbance, Dependence, and Sleep Disruption

Prescribing information lists insomnia, excitation, depression, habituation, and shifts in libido among the anabolic-steroid class effects in both sexes, consistent with androgen action on central nervous system arousal ([Orr & Fiatarone Singh, 2004](https://pubmed.ncbi.nlm.nih.gov/15025546/)). The evidence is uncontrolled: no oxandrolone trial has measured mood, sleep, or dependence formally.

**Magnitude:** Not quantified in available studies. These effects derive from prescribing information and spontaneous reports; no controlled oxandrolone trial has applied a validated mood, sleep, or dependence instrument.

#### Decreased Glucose Tolerance ⚠️ Conflicted

Prescribing information lists decreased glucose tolerance among the anabolic-steroid metabolic effects, while the one controlled measurement in older men found a derived insulin-sensitivity index improve ([Schroeder et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15472177/)). The net reading is that the label caution is unreproduced and bears mainly on established diabetes.

**Magnitude:** Not quantified in available studies. The label publishes no rate and the only controlled measurement moved in the opposite direction, so no figure describes this effect.

### Speculative 🟨

#### Androgen-Driven Erythrocytosis

Erythrocytosis (excess red blood cells) is a class effect of androgens stimulating red-cell production; prescribing information requires haematocrit checks at high anabolic-steroid doses. No oxandrolone trial has reported haematocrit, so the basis is class-label only.

#### Cholestatic Hepatitis and Jaundice

Cholestatic hepatitis (blocked bile flow, producing jaundice) is a labelled warning for 17α-alkylated androgens at even low doses, rarely progressing to liver failure. Reports involve other agents; no oxandrolone trial has recorded it.

#### Peliosis Hepatis and Hepatic Tumours

Peliosis hepatis (blood-filled cavities in the liver) and hepatic adenomas are class warnings for 17α-alkylated androgens. Case reports involve other agents; oxandrolone's 2-oxa ring appears to spare this, and no controlled trial has observed it.

#### Prostate Stimulation in Men

Androgens can enlarge the prostate and accelerate existing prostate cancer, a labelled warning for the anabolic steroid class. No oxandrolone trial has measured prostate endpoints, so the basis is mechanistic and class-label only.

#### Gynaecomastia and Priapism in Men

Prescribing information lists gynaecomastia (breast enlargement in men) and priapism (persistent erection) among anabolic-steroid class effects. Oxandrolone does not aromatise to oestrogen, and no trial has recorded either, so the basis is class-label only.

#### Androgenic Scalp Hair Loss

Prescribing information lists male-pattern baldness among the androgenic effects, and oxandrolone is dihydrotestosterone-derived — the androgen that drives hair-follicle shrinkage. No oxandrolone trial has recorded scalp outcomes, so the basis is class-label only.

#### Long-Term Atherosclerotic Risk from Sustained Lipid Shift

No trial has followed oxandrolone users to cardiovascular events. The concern is extrapolation from the size and direction of the measured cholesterol changes, not from any observed outcome.

  
## Risk-Modifying Factors

- **Genetic polymorphisms:** a common UGT2B17 deletion (the enzyme tags androgens for urinary excretion) slows clearance and is frequent in East Asians. SRD5A2 variants (affecting the enzyme that makes potent androgen) matter little: oxandrolone is already 5α-reduced.

- **Baseline biomarker levels:** any pre-existing transaminase elevation, low HDL-C, or raised apolipoprotein B (the particle count marker of atherogenic lipoproteins) narrows the safety margin, because oxandrolone pushes all three in the wrong direction.

- **Sex-based differences in risk:** women carry the virilisation risk and reach effective exposure at half the male dose; men carry gonadal suppression, prostate stimulation, and the larger absolute lipid shift.

- **Pre-existing health conditions:** active liver disease, prostate or male breast cancer, hypercalcaemia (high blood calcium), advanced kidney disease, heart failure, thrombophilia (inherited clotting tendency), and diabetes each convert a manageable effect into a clinically significant one.

- **Age-related considerations:** younger patients had higher odds of transaminitis in multivariable analysis, the odds falling about 9% per five years of age. Older adults instead face prostate stimulation and the cardiovascular consequence of a sustained lipid shift.

  
## Key Interactions & Contraindications

- **Vitamin K antagonists (blood thinners — warfarin, acenocoumarol):** absolute contraindication without dose reduction. Oxandrolone can cut the warfarin requirement by up to 85%; the consequence is severe bleeding. Mitigation: pre-emptive dose reduction and international normalised ratio (standardised clotting time) checks every 2–3 days.

- **Insulin and oral glucose-lowering drugs (metformin, glipizide, glimepiride):** caution. Oxandrolone increases insulin sensitivity, so unchanged doses can produce hypoglycaemia (low blood sugar). Mitigation: close glucose monitoring during the first two weeks, with glucose-lowering dose reduction as needed.

- **Corticosteroids and corticotropin (prednisone, dexamethasone):** caution. Additive sodium and water retention producing oedema. Mitigation: daily weight and ankle checks; sodium restriction.

- **Hepatotoxic medications (amiodarone, methotrexate, isoniazid, high-dose acetaminophen):** caution. Additive transaminitis; amiodarone independently multiplied the odds of transaminitis 2.5-fold in treated adults. Mitigation: liver-stressing agents separated in time or omitted for the cycle.

- **Over-the-counter analgesics (acetaminophen, ibuprofen, naproxen):** caution. Acetaminophen adds hepatic load; non-steroidal anti-inflammatory drugs add sodium retention and blood pressure elevation. Mitigation: an acetaminophen ceiling of 2 g/day, with topical anti-inflammatories preferred.

- **Androgenic supplements (DHEA — dehydroepiandrosterone, an adrenal androgen precursor — androstenedione, *Tribulus terrestris* preparations):** caution. Additive androgen load raising virilisation and gonadal-suppression risk without measurable extra anabolic effect. Mitigation: suspension for the duration.

- **Hepatically burdensome supplements (red yeast rice, high-dose green tea extract, kava):** caution. Additive transaminase elevation confounds monitoring and can force an unnecessary stop. Mitigation: discontinuation before starting, with reintroduction after the post-cycle liver panel is clear.

- **Creatine monohydrate:** monitor. No pharmacokinetic interaction, but additive on lean mass, and it raises serum creatinine independently of kidney function, which can be misread as kidney injury. Mitigation: kidney markers read via cystatin C while supplementing.

- **Other interventions — testosterone therapy and growth hormone:** caution. Testosterone is additive on both anabolic effect and gonadal suppression; growth hormone is additive on anabolic effect and on fluid retention. Mitigation: androgens are not stacked; oxandrolone substitutes for testosterone rather than adding to it.

- **5α-reductase inhibitors (finasteride, dutasteride — drugs that block the enzyme making the body's most potent androgen):** no interaction of consequence. Oxandrolone is already 5α-reduced, so these agents neither blunt its androgenic effect nor protect the scalp or prostate from it.

**Populations who should avoid Oxandrolone:**

- Anyone pregnant, attempting conception, or breastfeeding — the drug is teratogenic and carries a Pregnancy Category X designation.
- Known or suspected prostate carcinoma, or carcinoma of the male breast.
- Women with breast cancer and hypercalcaemia (serum calcium above 10.5 mg/dL).
- Advanced kidney disease (estimated glomerular filtration rate below 30 mL/min/1.73 m²) or nephrotic syndrome (heavy protein loss in the urine).
- Active liver disease, Child-Pugh Class B or C cirrhosis (the moderate-to-severe grades of liver impairment), or baseline ALT or AST (alanine and aspartate aminotransferase, the enzymes released by injured liver cells) above three times the upper limit of normal.
- Severe heart failure (New York Heart Association Class III–IV, meaning symptoms at minimal exertion or at rest).
- Venous thromboembolism within the last 90 days, or a known inherited clotting disorder.
- Anyone on warfarin who cannot access international normalised ratio testing every two to three days.

  
## Risk Mitigation Strategies

- **Fixed-duration cycle with a pre-set stop date:** six to twelve weeks, never open-ended. Limits cumulative hepatic and lipid exposure, both of which are duration-dependent; it also prevents the indefinite gonadal suppression that follows continuous use.

- **Lowest effective dose, titrated up:** protocols start at 2.5 mg twice daily, moving to 5 mg twice daily after two weeks if liver enzymes hold. Transaminitis and lipid shift are dose-related, and most of the effect appears by six weeks.

- **Liver enzymes at weeks 2 and 4, then monthly:** dosing stops if ALT or AST exceeds three times the upper limit of normal, or at any bilirubin rise. Transaminitis appears at a median 13 days, so late-only testing misses it.

- **Lipid panel with apolipoprotein B at baseline, week 4, and post-cycle:** documents the HDL-C fall and LDL-C rise and sets the threshold for abandoning the cycle rather than discovering the damage months later.

- **Alcohol abstinence and removal of hepatotoxic co-medications and supplements for the cycle:** amiodarone, methotrexate, red yeast rice, and high-dose green tea extract each compound the transaminitis risk and confound its attribution.

- **Female dose ceiling of 10 mg daily with a voice-change stop rule:** voice deepening is the least reversible virilising effect. Stopping at the first perceived hoarseness prevents a permanent change.

- **Post-cycle endocrine reassessment at 8 to 12 weeks:** total and free testosterone with luteinising hormone confirms recovery of the gonadal axis rather than assuming it, and detects the prolonged suppression that would argue against repeating.

- **Mobility and clot vigilance:** protocols exclude prolonged immobility and long-haul travel during the cycle, and rate unilateral calf swelling or unexplained breathlessness as urgent, given the thromboembolic signal in treated cohorts.

  
## Therapeutic Protocol

- **Licensed adult regimen:** 2.5–20 mg daily in two to four divided doses for two to four weeks, repeated intermittently; 5 mg twice daily in older adults. This is the labelled schedule for restoring weight lost to trauma or surgery.

- **Research regimen used for muscle outcomes:** 20 mg daily as 10 mg twice daily for six to twelve weeks. This is the exposure behind every reported lean-mass and strength figure in older adults, and behind the burn-unit protocols.

- **Conventional critical-care approach:** short, higher-dose courses given alongside aggressive protein feeding, popularised by David Herndon's group at Shriners Hospitals in Galveston and by Robert Demling at Brigham and Women's Hospital.

- **Alternative low-dose intermittent approach:** 5 to 10 mg daily in cycles, favoured in longevity and functional practice to limit lipid and hepatic exposure. Neither approach has been tested against the other in a randomised trial.

- **Testosterone as the competing regimen:** injectable testosterone is now the default anabolic agent in United States burn care, argued for by Paul Wischmeyer's group at Duke, on grounds of availability, cost, and a comparative mortality signal.

- **Best time of day:** doses are taken with food, morning and evening. No circadian advantage has been demonstrated; food reduces gastric upset without meaningfully changing absorption of a nearly fully bioavailable compound.

- **Half-life and dosing frequency:** the elimination half-life of roughly 9.4 hours in adults, and about 13.3 hours past 65, is the reason every trial used split rather than single daily dosing.

- **Single versus split dosing:** split. Twice-daily dosing maintains receptor occupancy across the day; single daily dosing has never been used in a trial reporting a muscle outcome.

- **Genetic polymorphisms influencing dose:** a UGT2B17 deletion slows androgen clearance and argues for the lower end of the range; androgen receptor CAG repeat length plausibly modifies response but has no validated dose rule.

- **Sex-based differences in dosing:** women in trials reached a comparable protein-synthesis response at 15 mg daily versus 20 mg in men, and the female virilisation ceiling is lower, so 5 to 10 mg daily is the practical range.

- **Age-related considerations:** adults past 60 gain mass and strength on standard doses, but leg power and walking speed did not improve even in the oldest participants studied, so the endpoint the evidence supports is mass, not function.

- **Baseline biomarkers influencing response:** low starting testosterone predicts a larger body-composition response; normal starting liver enzymes and HDL-C widen the safety margin within which the dose can be escalated.

- **Pre-existing conditions influencing response:** high catabolic drive amplifies the effect, while established acute lung injury reverses it. Liver disease, uncontrolled diabetes, and heart failure each argue for the lowest dose or none.

  
## Discontinuation & Cycling

- **Short-term by design:** the licensed course is two to four weeks and no trial has run beyond twelve months. This is not a lifelong intervention, and no safety data support continuous use in healthy adults.

- **Loss of gains after stopping:** twelve weeks after withdrawal, lean mass and strength had returned to baseline in older men, while the fat reduction was largely retained. Benefits to muscle are exposure-dependent, not durable.

- **No tapering required:** oxandrolone has no dose-dependent withdrawal syndrome and is stopped outright at the end of a cycle. Tapering offers no pharmacological advantage given the short half-life.

- **Withdrawal effects:** the main consequence is the interval before the suppressed gonadal axis recovers, during which fatigue, low libido, and low mood are plausible. Recovery time has not been formally characterised in any oxandrolone trial.

- **Cycling for sustained efficacy:** the label itself specifies intermittent repetition. A practical pattern is six to twelve weeks on followed by at least eight to twelve weeks off, with liver enzymes, lipids, and testosterone confirmed normal before repeating.

  
## Sourcing and Quality

- **No approved United States product:** oxandrolone has been discontinued in the United States, so no branded or generic Oxandrin-equivalent tablet is commercially available there. The former products were Oxandrin and generics from Par Pharmaceutical and Upsher-Smith.

- **Compounding pharmacies as the remaining legal route:** a prescription can be filled by a 503A compounding pharmacy or a 503B outsourcing facility. What to look for is a facility registered with the Food and Drug Administration that issues a batch certificate of analysis.

- **Certificate of analysis contents:** identity by mass spectrometry, assay within 90–110% of label claim, and limits for residual solvents and heavy metals. A compounder unwilling to supply this document is unverified.

- **Counterfeit and substitution risk in the grey market:** tablets sold as "Anavar" are frequently substituted with cheaper, more androgenic and more hepatotoxic steroids. This is the single largest quality hazard, and no visual inspection detects it.

- **Third-party verification for material of uncertain origin:** independent mass-spectrometry testing services will assay a tablet for identity and dose. This is the only meaningful check on non-pharmacy material, and it does not address sterility or excipient quality.

- **Non-United States generics:** licensed oxandrolone tablets remain marketed in some other jurisdictions. Import rules vary and a Schedule III controlled substance cannot lawfully be imported into the United States for personal use.

  
## Practical Considerations

- **Time to effect:** measurable change is fast. Lean mass and maximal strength rise within six weeks, and most of the twelve-week gain in both is already present at six weeks — an unusually short window for any anabolic intervention.

- **Common pitfall — running it without a training stimulus:** in trained older women, oxandrolone added mass but no strength or power beyond resistance training. Without loading, the added tissue does not reliably become usable function.

- **Common pitfall — treating it as continuous therapy:** every trial reporting benefit used a defined course. Open-ended use accumulates hepatic, lipid, and endocrine cost with no evidence of additional gain past twelve weeks.

- **Common pitfall — skipping early liver testing:** transaminitis appears at a median of thirteen days. Testing only at the end of a cycle reliably misses the window in which stopping would have been the right response.

- **Regulatory status:** a Schedule III controlled substance in the United States, requiring a prescription and carrying diversion controls. It is prohibited at all times by the World Anti-Doping Agency, and any use for muscle preservation in a healthy adult is off-label.

- **Cost and accessibility:** access, not price, is the binding constraint. United States manufacture has ended, so supply depends on unreimbursed compounding, while generic injectable testosterone is far cheaper — giving payers a structural financial reason to favour testosterone in guidelines and research funding.

  
## Interaction with Foundational Habits

- **Sleep:** direct and generally negative. Insomnia and a sense of excitation are listed among the common effects, and androgens can worsen sleep-disordered breathing. Practically, protocols place both doses before late afternoon, and in anyone with existing snoring or apnoea the drug is likely to aggravate it.

- **Nutrition:** potentiating, and strictly conditional. Oxandrolone supplies an anabolic signal but no substrate, so the reported gains assumed generous protein and energy. A practical target is 1.6 to 2.2 g of protein per kilogram of body weight daily with at least maintenance calories; an energy deficit converts the drug into a fat-loss agent instead.

- **Exercise:** potentiating for mass, neutral for strength once training is serious. Combined with a twelve-week exercise programme after severe burns it produced greater lean mass and strength than either alone, yet added no strength or power to progressive resistance training in older women. Timing relative to dosing is not established.

- **Stress management:** indirect and favourable. A principal anti-catabolic action is opposition to glucocorticoid-driven protein breakdown, the same pathway that chronic psychological stress and poor sleep drive upward. Cortisol-lowering practices therefore act on the same target and reduce the work the drug has to do.

  
## Monitoring Protocol & Defining Success

Baseline testing establishes whether the two systems oxandrolone stresses — liver and lipoproteins — start from a safe position, and fixes the hormonal and body-composition reference point against which change is read. The usual set is a full liver panel, a fasting lipid panel with apolipoprotein B, total and free testosterone with luteinising hormone and sex hormone-binding globulin, a complete blood count, serum calcium, and a dual-energy X-ray absorptiometry scan (DEXA, a low-dose X-ray scan that separates fat, lean tissue, and bone) for lean mass; men past 40 add prostate-specific antigen.

Ongoing monitoring is front-loaded, because transaminase rises appear at a median of about two weeks. Liver enzymes are repeated at 2 and 4 weeks and then monthly while dosing continues; lipids at 4 weeks and at the end of the cycle; hormones and body composition at the end of the cycle and again 8 to 12 weeks after stopping.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| ALT | Men <25 U/L, women <20 U/L | Earliest and most frequent signal of hepatic stress | ALT is alanine aminotransferase. Conventional labs flag only above 40–55 U/L; the functional target is far tighter. Fasting not required. Dosing stops at >3× the upper limit of normal |
| AST | <25 U/L | Confirms hepatic origin when paired with ALT | AST is aspartate aminotransferase. Conventional labs flag only above about 40 U/L; the functional target is tighter. It rises with muscle damage too, so it is interpreted alongside creatine kinase (a muscle enzyme that leaks into blood after muscle damage) after heavy training. Drawn before, not after, a hard session |
| GGT | <20 U/L | Distinguishes drug-related cholestasis (slowed bile flow) from muscle-derived enzyme rise | GGT is gamma-glutamyl transferase, a bile-duct enzyme. Conventional upper limit is about 50–65 U/L. Best paired with ALT and bilirubin; sensitive to alcohol, which protocols exclude during a cycle |
| Total bilirubin | 0.3–1.0 mg/dL | Detects the shift from harmless enzyme rise to actual liver dysfunction | Any rise on treatment is a stop signal regardless of enzyme values. Gilbert's syndrome (a harmless inherited variation in bilirubin handling) raises it benignly, which the baseline establishes |
| HDL-C | Men >50 mg/dL, women >60 mg/dL | The lipid fraction oxandrolone suppresses most sharply | Conventional cut-off is 40 mg/dL for men, which is too permissive here. Fasting 12 hours; a fall of roughly a third is expected |
| Apolipoprotein B | <80 mg/dL, or <60 mg/dL at high cardiovascular risk | Counts atherogenic particles, the endpoint that matters as LDL-C rises | Conventional panels report LDL-C only; apolipoprotein B is the better risk marker. Fasting preferred, best paired with the lipid panel |
| Total and free testosterone | Total 600–900 ng/dL, free 15–25 pg/mL (men); women, no established target — track change from personal baseline | Quantifies suppression of the gonadal axis and its recovery | Conventional range starts at 300 ng/dL, far below the functional target. Drawn 7–10 a.m. fasted; repeated 8–12 weeks post-cycle |
| LH | 2–8 IU/L | Confirms whether suppression is central and whether it has resolved | LH is luteinising hormone, the pituitary signal that drives testicular testosterone output. Paired with testosterone and sex hormone-binding globulin in one morning draw; a suppressed value with low testosterone confirms drug effect |
| Haematocrit | Men 40–48%, women 36–44% | Detects androgen-driven thickening of the blood, which compounds the clot signal | Conventional upper limit is 52%; action comes well before that. Affected by hydration, so drawn well hydrated and at a consistent time |
| PSA, men over 40 | <1.0 ng/mL under 60; <2.0 ng/mL over 60 | Androgen exposure can accelerate existing prostate pathology | PSA is prostate-specific antigen, a protein released by prostate tissue. The conventional cut-off is 4.0 ng/mL, far above the functional target. A draw within 48 hours of cycling or ejaculation is unreliable. Rate of change over time matters more than any single value |
| Lean body mass by DEXA | No established target — track change from the individual's own baseline, aiming for a gain of 1 kg or more over 12 weeks | The primary success measure for the stated goal | Scanned fasted, same machine, same time of day. Hydration shifts the reading; part of any early gain is intracellular water |

Qualitative markers tracked alongside the laboratory set:

- Training performance: session-to-session load and repetition progression on two or three fixed compound lifts, which detects usable strength rather than measured tissue.
- Recovery quality: perceived soreness duration and readiness to train hard again, which typically shortens before any measurable change in mass.
- Sleep quality and continuity: nights to sleep onset and night-time awakenings, given the documented insomnia and excitation.
- Mood and drive: irritability, restlessness, and shifts in libido in either direction.
- Voice and skin in women: any hoarseness, new acne, or accelerated facial hair growth, checked weekly, since these mark the point at which stopping preserves reversibility.
- Ankle and finger swelling and morning body weight, which distinguishes fluid retention from genuine tissue gain.

  
## Emerging Research

- **Implantable oxandrolone pellet after knee ligament reconstruction:** [NCT06974526](https://clinicaltrials.gov/study/NCT06974526), a Phase 2 trial of a bioabsorbable subdermal oxandrolone pellet in 96 participants after anterior cruciate ligament reconstruction, recruiting since late 2025, with serious adverse events over 24 weeks as the primary endpoint.

- **Oxandrolone after multiligament knee injury:** [NCT05893069](https://clinicaltrials.gov/study/NCT05893069), a Phase 4 trial in 60 participants taking lean body mass and body fat percentage as co-primary endpoints — the closest registered test of the muscle-preservation claim in otherwise healthy adults. Currently suspended.

- **Head-to-head comparison against testosterone:** [Hong et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42518198/) analysed 813 adults across twelve burn centres and found no weight-maintenance advantage for anabolic therapy, longer stays, more clots, and higher mortality with oxandrolone than testosterone. This weakens the case substantially.

- **Anabolic therapy within multimodal recovery:** [Wischmeyer, 2026](https://pubmed.ncbi.nlm.nih.gov/41954304/) reviews where oxandrolone sits against testosterone, creatine, and beta-hydroxy-beta-methylbutyrate, and notes a randomised trial of nandrolone for intensive-care-acquired weakness now under way.

- **Unresolved heterogeneity in the burn evidence:** [Lou et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41023744/) report between-study inconsistency above 95% for the lean-mass and length-of-stay outcomes, meaning the pooled effect sizes that underpin the benefit case may not be stable.

- **The missing sarcopenia outcome trial:** [Orr & Fiatarone Singh, 2004](https://pubmed.ncbi.nlm.nih.gov/15025546/) observed that oxandrolone had never been studied in sarcopenia. Short randomised work in older adults has since measured mass and function, but no trial has followed disability, falls, or independence — the test that would most change current understanding.

  
## Conclusion

Oxandrolone is a man-made relative of testosterone, given as an oral medication, built to add and hold muscle with less of the masculinising effect of the parent hormone. The firmest evidence, replicated across more than one controlled trial, is that it adds lean tissue in older adults, blunts muscle loss in people recovering from severe burns, and raises maximal lifting strength in the untrained — though adding it to a supervised weight-training programme produced no strength beyond what the training delivered on its own. Whatever tissue it adds fades within about three months of stopping, while the loss of body fat it produces lasts considerably longer.

Set against that is a consistent and largely predictable cost: liver enzymes rise in a substantial minority of users, protective blood fats fall sharply while the harmful fraction rises, the body's own testosterone production shuts down, and women face masculinising changes of which voice deepening is the least reversible. These are ordinary consequences of the drug rather than rare misfortunes.

The evidence base is narrower than its age suggests. Most of it comes from a small circle of burn and academic centres, some of it supported by the company that once sold the drug — a financial interest that colours how uniformly favourable the benefit findings read. None of it comes from trials in healthy ageing adults followed long enough to show whether added tissue becomes lasting function.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**